Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02723006
Title Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Millennium Pharmaceuticals, Inc.
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Arizona Cancer Center Tucson Arizona United States Details
University of California Los Angeles - Jonsson Comprehensive Cancer Center Los Angeles California United States Details
University of California San Francisco Medical Center San Francisco California United States Details
University of Colorado Cancer Center Aurora Colorado United States Details
Emory University Hospital Atlanta Georgia United States Details
Dana-Farber Cancer Institute Boston Massachusetts United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts United States Details
Virginia Piper Cancer Institute Minneapolis Minnesota United States Details
Washington University School of Medicine Saint Louis Missouri United States Details
New York University Langone Medical Center New York New York United States Details
Saint Luke's Cancer Center - Bethlehem Easton Pennsylvania United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania United States Details
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas United States Details
Inova Fairfax Hospital Fairfax Virginia United States Details
*Shaded cells indicate that there was no data available from for the field